Insomnia and sleep quality are huge issues in the population. Anytime a safe, effective, natural agent can be used to help, this is welcomed news. Harold Robinson, CEO, JayMac Pharmaceuticals
Sunset, LA (PRWEB) February 26, 2014
Mild to moderate depression is affecting up to 10% of the U.S. population. Insomnia, headache, fatigue, and pain are a few of the physical complaints associated with this mood disorder.
While the benefit in management of depressive symptoms has been well documented, the effect of EnLyte Rx on sleep has not been explored. In an effort to assess the degree to which fatigue and resultant emotional dysregulation might be improved, Arnold Mech, MD, of Mech Healthcare Associates, added EnLyte Rx in an open-label fashion to the treatment regimen of 60 patients in an outpatient neuropsychiatry clinic who had tested positive for one or two C677T allele MTHFR single nucleotide substitutions. Pre- and post-EnLyte Rx levels of fatigue were obtained per standard clinic protocol using the Fatigue Assessment Scale (FAS) and levels of emotional dysregulation (difficulties in frustration tolerance and impulse control) with the Mech Emotional Dysregulation Inventory (MEDI).
Patients took EnLyte Rx in an open label manner for 4-weeks. Most patients reported their sleep was significantly improved. This was demonstrated on the Fatigue Assessment inventories completed by patients pre- and post-EnLyte Rx administration where patients reported improvements in sleep quality with a 22% reduction in fatigue and a 41% reduction in related emotional dysregulation (i.e., impaired frustration tolerance and impulse control.)
Virtually all clinical reports on mood disorders identify neurotransmitter imbalances as contributors to either the root cause or the symptoms of depression and anxiety. Addressing neurotransmitter imbalances is a highly effective approach for successful clinical outcomes in terms of targeted treatment, cost, and compliance. EnLyte Rx is a unique combination of metabolized folates, omega III's, and minerals needed to maximize neurotransmitters through the remethylation and transsulfuration cycles.
Harold Robinson, CEO of JayMac Pharmaceuticals, the makers of EnLyte Rx, states, “We are excited about the results of this study, and we will be doing further studies to determine more specific quantitative measures of sleep improvement with EnLyte Rx. Insomnia and sleep quality are huge issues in the population, and anytime a safe, effective, natural agent can be used to help, this is welcomed news.”